间苯三酚对羟考酮复合丙泊酚用于宫腔镜检查麻醉效果的影响
| 作者: |
1王兰,
2刘伟,
1张于,
1李庆辉,
1王春光
1 保定市第一中心医院麻醉科，河北 保定 071000 2 保定市第一中心医院妇产科，河北 保定 071000 |
| 通讯: |
王春光
Email: wangchunguang@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.10.010 |
摘要
目的：观察间苯三酚对羟考酮复合丙泊酚用于宫腔镜检查麻醉效果的影响。方法：选择2018年 5至10月行无痛宫腔镜检查的患者60例，美国麻醉医师协会(American Society of Anesthesiologists， ASA)分级I~II级，年龄32~56岁，体重45~61 kg，随机分为间苯三酚组(P组)与对照组(C组)，每组各30例。宫腔镜检查前15 min，P组静脉注射间苯三酚80 mg，C组静脉注射5%葡萄糖溶20 mL。两组患者均注射羟考酮0.06 mg/kg后，再静脉注射丙泊酚2.5 mg/kg。术中出现皱眉或体动反应时，静脉追加丙泊酚0.5 mg/kg。记录注射间苯三酚前(T0)、注射间苯三酚后10 min(T1)、注射间苯三酚后15 min(T2)、诱导后2 min(T3)、进镜后1 min(T4)及进镜后5 min(T5)各时间点的生命体征。记录检查过程中皱眉或体动例数及丙泊酚的用量；记录宫腔镜检查时间及苏醒时间；记录呼吸抑制、头晕、恶心呕吐等不良反应发生情况；记录苏醒后5，10，30 min的视觉模拟(Visual Analogue Scale， VAS)评分及苏醒后30 min患者满意度。结果：与C组比较，P组检查时间、苏醒时间及丙泊酚用量减少(P<0.05)；与C组比较，P组皱眉、体动发生率降低(P<0.05)；与C组比较，P组T4，T5时点平均动脉压降低(P<0.05)；与C组比较，P组T4，T5时点心率(heart rate，HR)降低(P<0.05)；与C组比较，P组苏醒后VAS评分降低(P<0.05)；两组患者满意度及呼吸抑制、头晕、恶心呕吐等不良反应发生率差异无统计学意义(P>0.05)。结论：间苯三酚可改善羟考酮复合丙泊酚用于宫腔镜检查的麻醉效果，降低患者疼痛程度，减少丙泊酚用量。
关键词：
间苯三酚；羟考酮；宫腔镜
Effect of phloroglucinol on anesthesia of oxycodone combined with propofol for hysteroscopy
CorrespondingAuthor: WANG Chunguang Email: wangchunguang@163.com
DOI: 10.3978/j.issn.2095-6959.2019.10.010
Abstract
Objective: To observe the effect of phloroglucinol on anesthesia of oxycodone combined with propofol for hysteroscopy. Methods: Sixty patients underwent hysteroscopy were included in this study from May 2018 to October 2018. Those patients, American Society of Anesthesiologists (ASA) I–II, aged 32 to 56 years, weighing 45–61 kg, were divided into two groups (30 cases for each): phloroglucinol group (Group P) and control group (Group C). Fifteen minutes before hysteroscopy, patients were intravenously injected with phloroglucinol 80 mg in Group P and 5% glucose solution 20 mL in Group C. And then, all patients were intravenously injected with oxycodone (0.06 mg/kg) and propofol (2.5 mg/kg). When movement occurred during hysteroscopy, propofol (0.5 mg/kg) was intravenously injected additionally. The MAP, HR and SpO2 was recorded at the time points of before the injection of phloroglucinol, 10 min after the injection of phloroglucinol, 15 min after the injection of phloroglucinol, 2 minutes after induction, 1 and 5 minutes after hysteroscopy. The occurrence of frown or body movement and dosage of propofol were recorded. Time of hysteroscopy and the waking time were record. The occurrence of respiratory depression, dizziness, nausea and vomiting were recorded. The scores of Visual Analogue Scale (VAS) and degree of satisfaction were recorded. Results: Compared with Group C, the time of hysteroscopy, waking time and dosage of propofol decreased in Group P (P<0.05). Compared with Group C, the incidence of frown, body movement decreased in Group P (P<0.05). Compared with Group C, MAP and HR decreased in Group P at the time point of 1 and 5 minutes after hysteroscopy (P<0.05). Compared with Group C, the scores of VAS decreased in Group P (P<0.05). For degree of satisfaction and the occurrence of respiratory depression, dizziness and nausea and vomiting, there was no difference between Group P and Group C (P>0.05). Conclusion: Phloroglucinol could improve the anesthesia effect of oxycodone combined with propofol for hysteroscopy, decrease the degree of pain and the dosage of propofol.
Keywords：
phloroglucinol; oxycodone; hysteroscopy